Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 13 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-3.92 Insider Own0.53% Shs Outstand11.64M Perf Week11.34%
Market Cap310.79M Forward P/E- EPS next Y-1.20 Insider Trans0.00% Shs Float11.58M Perf Month4.34%
Income-45.09M PEG- EPS next Q-0.26 Inst Own65.83% Short Float2.31% Perf Quarter3.61%
Sales5.81M P/S53.49 EPS this Y56.35% Inst Trans0.91% Short Ratio19.10 Perf Half Y80.53%
Book/sh7.07 P/B3.78 EPS next Y31.95% ROA-22.44% Short Interest0.27M Perf Year55.41%
Cash/sh11.75 P/C2.27 EPS next 5Y19.00% ROE-40.24% 52W Range13.48 - 27.00 Perf YTD44.32%
Dividend Est.- P/FCF- EPS past 5Y-20.43% ROI-22.86% 52W High-1.11% Beta0.94
Dividend TTM- Quick Ratio9.45 Sales past 5Y46.25% Gross Margin87.51% 52W Low98.07% ATR (14)1.12
Dividend Ex-Date- Current Ratio9.45 EPS Y/Y TTM-49.10% Oper. Margin-393.29% RSI (14)60.46 Volatility4.37% 4.23%
Employees13 Debt/Eq1.47 Sales Y/Y TTM73.10% Profit Margin-775.86% Recom1.67 Target Price58.00
Option/ShortYes / Yes LT Debt/Eq1.39 EPS Q/Q11.81% Payout- Rel Volume1.86 Prev Close25.01
Sales Surprise11.47% EPS Surprise-21.13% Sales Q/Q240.96% EarningsMay 09 BMO Avg Volume14.01K Price26.70
SMA207.56% SMA506.32% SMA20031.01% Trades Volume26,015 Change6.76%
Date Action Analyst Rating Change Price Target Change
Apr-29-24Initiated Leerink Partners Outperform $40
Sep-07-21Downgrade Wedbush Outperform → Neutral $22
Jun-29-21Initiated Aegis Capital Buy $60
Jan-19-21Reiterated H.C. Wainwright Buy $30 → $56
Jan-18-18Reiterated H.C. Wainwright Buy $38 → $49
Oct-17-17Resumed H.C. Wainwright Buy $38
Sep-05-17Upgrade Wedbush Neutral → Outperform $9 → $19
Jun-12-17Initiated H.C. Wainwright Buy $15
Nov-14-16Downgrade Wedbush Outperform → Neutral $17 → $14
Mar-11-16Reiterated Wedbush Outperform $6 → $3
Jun-12-24 07:30AM
May-14-24 07:30AM
May-10-24 03:18PM
May-09-24 01:55PM
08:00AM Loading…
May-07-24 10:00AM
Apr-30-24 07:30AM
Apr-25-24 07:30AM
Apr-24-24 09:00AM
Apr-03-24 09:00AM
Mar-21-24 07:30AM
Mar-19-24 04:05PM
Mar-08-24 12:53PM
08:12AM Loading…
Feb-28-24 07:30AM
Feb-16-24 08:00AM
Jan-18-24 08:30AM
Jan-11-24 04:05PM
Jan-08-24 07:30AM
Jan-02-24 07:30AM
Dec-20-23 07:30AM
Dec-19-23 07:30AM
Nov-07-23 07:50AM
Oct-31-23 07:30AM
Sep-25-23 07:30AM
07:30AM Loading…
Sep-06-23 07:30AM
Aug-31-23 10:43PM
Aug-13-23 10:07AM
Aug-08-23 08:21AM
Jun-23-23 06:14PM
Jun-22-23 07:30AM
Jun-20-23 07:30AM
May-16-23 09:29AM
May-09-23 07:53AM
Apr-26-23 07:30AM
Mar-30-23 07:30AM
Mar-21-23 07:30AM
Mar-10-23 05:36AM
Mar-09-23 07:50AM
Mar-06-23 08:28AM
Feb-28-23 07:30AM
Jan-06-23 07:00PM
Jan-04-23 07:30AM
Dec-22-22 07:30AM
Dec-07-22 07:44AM
Nov-22-22 07:01AM
Nov-06-22 09:24AM
Nov-03-22 09:05AM
Sep-27-22 08:30AM
Sep-21-22 07:30AM
Sep-07-22 07:30AM
Sep-01-22 06:20AM
Aug-11-22 06:22AM
Aug-04-22 10:45AM
Jun-30-22 07:33AM
Jun-20-22 07:30AM
Jun-02-22 01:00AM
May-30-22 07:06AM
May-17-22 04:05PM
May-07-22 08:27AM
May-05-22 08:55AM
May-03-22 08:15AM
Apr-20-22 08:24AM
Mar-21-22 07:30AM
Mar-15-22 06:21AM
Mar-10-22 09:43AM
Mar-08-22 07:30AM
Mar-01-22 07:30AM
Feb-17-22 07:30AM
Jan-21-22 10:21AM
Dec-23-21 07:30AM
Dec-21-21 07:30AM
Dec-16-21 07:30AM
Nov-22-21 11:46AM
Nov-15-21 06:01AM
Nov-04-21 10:15AM
Oct-28-21 03:06PM
Oct-27-21 04:50AM
Oct-14-21 06:57AM
Oct-08-21 03:35AM
Sep-22-21 07:30AM
Sep-21-21 12:33PM
Sep-20-21 07:30AM
Sep-13-21 07:30AM
Sep-07-21 01:49PM
Aug-10-21 04:35PM
XOMA Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets that provides right to future potential royalty and milestone payments. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sitko BradleyChief Investment OfficerOct 03 '23Buy13.892503,4725,600Oct 04 04:30 PM
Sitko BradleyChief Investment OfficerOct 02 '23Buy14.251,50021,3755,350Oct 04 04:30 PM
Hughes OwenExec Chairman and Interim CEOOct 02 '23Buy13.831,00013,8303,500Oct 04 04:30 PM
Hughes OwenExec Chairman and Interim CEOSep 26 '23Buy14.432,49936,0612,500Sep 27 04:30 PM
Hughes OwenExec Chairman and Interim CEOSep 25 '23Buy14.651151Sep 27 04:30 PM